Early proteinuria response: A valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?

Lupus Science and Medicine

Volumn 4, Issue 1, 2017, Pages

  Ugolini Lopes, Michelle R ^a   Seguro, Luciana Parente C ^a   Castro, Maitê Xavier F ^a   Daffre, Danielle ^a   Lopes, Alex C ^a   Borba, Eduardo F ^a   Bonfá, Eloisa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Lupus Nephritis; Outcome research; Proteinuria; Systemic Lupus Erythematosus

Indexed keywords

CREATININE; DOUBLE STRANDED DNA;

ADULT; ARTICLE; BLACK PERSON; CAUCASIAN; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; ERYTHROCYTE; ETHNICITY; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; LONGITUDINAL STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEINURIA; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SURVIVAL;

EID: 85020530634     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2017-000213     Document Type: Article

References (25)

1. Majdan M. [Treat-to-target in rheumatology]. Wiad Lek 2015;68:259-64.
2. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006;54:421-32.
3. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771-82.
4. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
5. Gordon C, Sutcliffe N, Skan J, et al. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology 2003;42:1372-9.
6. Klumb EM, Silva CA, Lanna CC, et al. [Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis]. Rev Bras Reumatol 2015;55:1-21.
7. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
8. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
9. Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014;66:379-89.
10. ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol 2014;66:3096-104.
11. Corapi KM, Dooley MA, Pendergraft WF. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res Ther 2015;17:110.
12. Dall'Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 2015;67:1305-13.
13. Tamirou F, Lauwerys BR, Dall'Era M, et al. A proteinuria cut-off level of 0. 7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med 2015;2:e000123.
14. Oliveira-Santos M, Verani JF, Klumb EM, et al. Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil. Lupus 2011;20:320-9.
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
16. Chen YE, Korbet SM, Katz RS, et al. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008;3:46-53.
17. Contreras G, Lenz O, Pardo V, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006;69:1846-51.
18. Isenberg D, Appel GB, Contreras G, et al. Influence of race/ ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 2010;49:128-40.
19. Collado MV, Dorado E, Rausch S, et al. Long-term outcome of lupus nephritis class II in Argentine patients: an open retrospective analysis. J Clin Rheumatol 2016;22:299-306.
20. Hanly JG, Su L, Urowitz MB, et al. A longitudinal analysis of outcomes of lupus nephritis in an international inception cohort using a multistate model approach. Arthritis Rheumatol 2016;68:1932-44.
21. Parikh SV, Nagaraja HN, Hebert L, et al. Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephrol 2014;9:279-84.
22. Korbet SM, Schwartz MM, Evans J, et al. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007;18:244-54.
23. Austin HA, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983;75:382-91.
24. Appel GB, Cohen DJ, Pirani CL, et al. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987;83:877-85.
25. Tesar V. Moderator's view: cyclophosphamide in lupus nephritis. Nephrol Dial Transplant 2016;31:1058-61.